Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | BTK and PLCG2 mutations in CLL patients taking ibrutinib

Lydia Scarfò • 2 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Ibrutinib

Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, discusses Bruton’s tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCG2) mutations in chronic lymphocytic leukemia (CLL) patients receiving ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Lydia Scarfò

From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
2:34
From fixed-duration regimens to novel agents: current & future perspectives on CLL treatment
Lydia Scarfò • 4 Sep 2025
MRD assessment in CLL: importance of standardizing tests & potential clinical application
3:04
MRD assessment in CLL: importance of standardizing tests & potential clinical application
Lydia Scarfò • 4 Sep 2025
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
2:17
Tailoring therapy for younger, fit patients with CLL: advice for community oncologists
Lydia Scarfò • 5 Sep 2025
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
1:39
The importance of integrating genetic profiling in CLL: from NGS to emerging biomarkers
Lydia Scarfò • 4 Sep 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Lydia Scarfò • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Lydia Scarfò • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Lydia Scarfò • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Lydia Scarfò • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals